Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.

Détails

ID Serval
serval:BIB_BD3BE28C9923
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
Périodique
Gynecologic oncology
Auteur⸱e⸱s
Giannone G., Scotto G., Katsaros D., De Giorgi U., Farolfi A., Borella F., Cosma S., Ferrero A., Mangiacotti S., Villa M., Tuninetti V., Ghisoni E., Turinetto M., Mittica G., Gemmiti S., Zavallone L., Aglietta M., Pasini B., Di Maio M., Valabrega G.
ISSN
1095-6859 (Electronic)
ISSN-L
0090-8258
Statut éditorial
Publié
Date de publication
07/2021
Peer-reviewed
Oui
Volume
162
Numéro
1
Pages
80-87
Langue
anglais
Notes
Publication types: Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't ; Systematic Review
Publication Status: ppublish
Résumé
Hypersensitivity reactions (HSRs) to platinum are an important issue in the treatment of patients (pts) with ovarian cancer (OC). Germline BRCA mutations have been proposed as a risk factor. We aimed at evaluating the incidence and severity of HSRs to platinum in OC pts. with known BRCA status.
We retrospectively analyzed 432 pts. from 5 Italian Centers. In addition, we performed a systematic review and meta-analysis of published series.
Four hundred nine pts. received at least one prior platinum-based treatment line: 314 were BRCA wild type (77%) and 95 were BRCA mutated (23%). There was no statistical difference in exposure to platinum. Incidence of any grade HSRs was higher among BRCA mutated pts. [9% vs 18%, p = 0.019] and the time-to-HSRs curves show that the risk increases with the duration of platinum exposure, in BRCA mutated pts. more than in BRCA wild type. A multivariable analysis showed that harboring a germline BRCA mutation was related to a higher incidence of HSRs (HR: 1.84, 95% CI 1.00-3.99, p = 0.05) while having received pegylated liposomal doxorubicin (PLD) was related to a lower incidence of HSRs (HR: 0.03 95% CI 0.004-0.22, p = 0.001). The systematic review confirmed the higher incidence of HSRs in BRCA mutated pts., though heterogeneity among series was significant.
In OC pts. with BRCA mutations, there is a significantly higher incidence of HSRs to carboplatin, not justified by longer drug exposure. On the other hand, PLD exerted a protective role in our series.
Mots-clé
BRCA1 Protein/genetics, BRCA2 Protein/genetics, Drug Hypersensitivity/genetics, Female, Genes, BRCA1, Genes, BRCA2, Germ-Line Mutation, Humans, Multicenter Studies as Topic, Observational Studies as Topic, Organoplatinum Compounds/adverse effects, Organoplatinum Compounds/therapeutic use, Retrospective Studies, BRCA, Hypersensitivity reactions, Ovarian cancer, Platinum salts
Pubmed
Web of science
Création de la notice
11/05/2021 8:46
Dernière modification de la notice
21/01/2022 6:35
Données d'usage